Natco Pharma Share Price
(NATCOPHARM)
₹794.65
as on 01:21PM, 20 Feb 2025
🔔 Acquisition Alert
Natco Pharma is scouting for acquisitions in the US and RoW markets to strengthen its front-end business, according to CEO Rajeev Nannapaneni.
Natco Pharma Performance
Day's Low
Day's High
₹790.6Day's Price Range₹821.8552 Week's Low
52 Week's High
₹790.652-Week Price Range₹1,639
| Returns % | |
| 1 Month Return | -35.37 % |
| 3 Month Return | -40.86 % |
| 1 Year Return | -21.91 % |
| Market Stats | |
| Previous Close | ₹813.00 |
| Open | ₹794.15 |
| Volume | 11.11L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹14,561.63Cr |
Natco Pharma Key Statistics
P/E Ratio
7.81
PEG Ratio
0.23
Market Cap
₹14,561.63 Cr
P/B Ratio
3.05
EPS
77.56
Dividend Yield
1
Sector
Pharmaceuticals
ROE
25.38
Natco Pharma Mutual Fund Holdings
Natco Pharma Analyst Rating
based on 12 analysts
45.45%
Buy
18.18%
Hold
36.36%
Sell
Based on 12 analysts offering long term price targets for Natco Pharma. An average target of ₹1153.17
Source: S&P Global Market Intelligence
Natco Pharma Share analysis
Natco Pharma price forecast by 12 analysts
Upside of41.84%
High
₹1675
Target
₹1153.17
Low
₹710
Natco Pharma target price ₹1153.17, a slight upside of 41.84% compared to current price of ₹794.65. According to 12 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Natco Pharma revenue growth forecast
Expected growth rate Q1, FY2027:
Forecast
Actual
Including amortisation and stock based compensations
Natco Pharma EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
What's happening today
Today's Timeline - Invalid Date
12:13 PM
-Natco Pharma shares drop 40% over 10 days, hitting a 52-week low due to weak Q3 earnings.
Key events for Natco Pharma Ltd
Natco Pharma Faces Decline Amid Weak Earnings - 20 Feb, 2025
Natco Pharma's stock has fallen 40% over ten consecutive days, reaching a 52-week low following disappointing Q3 results, with a significant drop in revenue and profit. The company is exploring acquisitions to strengthen its market position amid challenges from potential tariff increases and competitive pressures.NATCO Pharma Declares Third Interim Dividend - 18 Feb, 2025
NATCO Pharma has announced a third interim dividend of ₹1.50 per equity share, representing 75% for the financial year 2024-25.Natco Pharma Faces Profit Decline, Dividend Announced - 17 Feb, 2025
Natco Pharma's share price dropped significantly due to a sharp decline in net profit and revenue. However, the company announced an interim dividend and saw a slight recovery in early trading.Natco Pharma Reports Significant Q3 Profit Decline - 12 Feb, 2025
Natco Pharma's Q3 FY25 results show a 37.8% decline in net profit to Rs 132.4 crore, with revenue down 37.4% to Rs 475 crore. The company faces operational challenges and declining margins, raising investor concerns.Natco Pharma Secures FDA Approval for Bosentan - 10 Feb, 2025
Natco Pharma has received final USFDA approval for Bosentan tablets for oral suspension, a generic version of Tracleer, allowing for 180-day exclusivity upon launch. The product targets pulmonary arterial hypertension in pediatric patients and had estimated U.S. sales of $11 million for the year ending September 2024.Natco Pharma Surpasses Resistance, Positive Momentum - 07 Feb, 2025
Natco Pharma's stock has broken through the resistance level of ₹1,275, indicating a potential trend reversal. Strong buying momentum and high volumes suggest a positive outlook, with expected upside targets of ₹1,420-1,460. The RSI indicates rising strength, supporting a buy-and-hold strategy.Natco Pharma Ltd Rises for Third Consecutive Session - 06 Feb, 2025
Natco Pharma Ltd shares increased by 3.15%, marking the third consecutive day of gains. The stock is currently priced at Rs 1324, up 54.09% over the past year, outperforming both NIFTY and Nifty Pharma index. Despite a slight drop of 0.18% in the last month, trading volume remains steady.Natco Pharma Secures FDA Approval for Everolimus - 30 Jan, 2025
Natco Pharma has received US FDA approval for its generic Everolimus tablets for oral suspension, targeting tuberous sclerosis complex, with estimated US sales of $112 million.
Insights on Natco Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 26.12% to 26.87% in Dec 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 17.51% to 17.94% in Dec 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 135.1% return, outperforming this stock by 141.3%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 59.9% return, outperforming this stock by 81.8%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 49.62% of holdings in Dec 2024 quarter
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 2.37% to 1.92% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, NATCOPHARM stock has moved down by -16.6%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 677.3 Cr → 133.0 Cr (in ₹), with an average decrease of 80.4% per quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 1.43K Cr → 651.1 Cr (in ₹), with an average decrease of 54.6% per quarter
Natco Pharma Financials
Index Inclusions
Natco Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 49.62% | 0.00 | |
| Foreign Institutions | 17.94% | 2.44 | |
| Mutual Funds | 1.92% | ||
| Retail Investors | 26.87% | 2.88 | |
| Others | 3.66% |
Natco Pharma Key Indicators
Natco Pharma Valuation
Natco Pharma in the last 5 years
Lowest (7.81x)
February 19, 2025
Today (7.81x)
February 19, 2025
Industry (51.87x)
February 19, 2025
Highest (90.32x)
April 6, 2022
Natco Pharma Earnings and Dividends
Natco Pharma Ltd Earnings Results
Natco Pharma Ltd’s net profit fell -37.47% since last year same period to ₹133Cr in the Q3 2024-2025. On a quarterly growth basis, Natco Pharma Ltd has generated -80.36% fall in its net profits since last 3-months.
Read More about Earnings ResultsNatco Pharma Ltd Dividends February,2025
In the quarter ending December 2024, Natco Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.89%.
Read More about Dividends
Natco Pharma Technicals Summary
Bearish
Neutral
Bullish
Natco Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.
Natco Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹14,561.63 Cr | 4.54% | 0.54 | ₹1,388 Cr | ₹3,998 Cr | |
| BUY | ₹12,048.61 Cr | -5.69% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹66,515.75 Cr | 17.86% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹89,700.73 Cr | 43.85% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹63,157.44 Cr | 18.28% | 0.53 | NA | NA |
About Natco Pharma
Share Price: ₹794.65 per share as on 20 Feb, 2025 01:21 PM
Market Capitalisation: ₹14,561.63Cr as of today
Revenue: ₹474.80Cr as on December 2024 (Q4 24)
Net Profit: ₹132.40Cr as on December 2024 (Q4 24)
Listing date: 27 Dec, 1995
Chairperson Name: G S Murthy
| Organisation | Natco Pharma |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Natco Pharma Ltd
What is Natco Pharma Ltd price today?
Natco Pharma Ltd share price today stands at ₹794.65, Open: ₹794.15, Previous Close: ₹813, High: ₹821.85, Low: ₹790.6, 52 Week High: ₹1639, 52 Week Low: ₹790.6.
How to Buy Natco Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Natco Pharma Ltd shares
Is Natco Pharma Ltd listed on NSE?
Natco Pharma Ltd is listed on NSE
Is Natco Pharma Ltd listed on BSE?
Natco Pharma Ltd is listed on BSE
What are today's High and Low prices of Natco Pharma Ltd?
- Today's highest price of Natco Pharma Ltd is ₹821.85.
- Today's lowest price of Natco Pharma Ltd is ₹790.6.
What are today's traded volumes of Natco Pharma Ltd?
Today's traded volume of Natco Pharma Ltd(NATCOPHARM) is 11.11L.
What is today's market capitalisation of Natco Pharma Ltd?
Today's market capitalisation of Natco Pharma Ltd(NATCOPHARM) is ₹14561.63Cr.
What is the 52 Week High and Low Range of Natco Pharma Ltd?
How much percentage Natco Pharma Ltd is down from its 52 Week High?
Natco Pharma Ltd (NATCOPHARM) share price is ₹794.65. It is down -51.52% from its 52 Week High price of ₹1639
How much percentage Natco Pharma Ltd is up from its 52 Week low?
Natco Pharma Ltd (NATCOPHARM) share price is ₹794.65. It is up 0.51% from its 52 Week Low price of ₹790.6
What are the historical returns of Natco Pharma Ltd?
What is the PE ratio of Natco Pharma Ltd today?
PE Ratio of Natco Pharma Ltd is 7.81
PE ratio = Natco Pharma Ltd Market price per share / Natco Pharma Ltd Earnings per share